Personalized Treatment of Alcohol Dependence

Pharmacogenetic and adaptive treatment approaches can be used to personalize care for alcohol-dependent patients. Preliminary evidence shows that variation in the gene encoding the μ-opioid receptor moderates the response to naltrexone when used to treat alcohol dependence. Studies have also shown moderating effects of variation in the gene encoding the serotonin transporter on response to serotonergic treatment of alcohol dependence. Adaptive algorithms that modify alcohol treatment based on patients’ progress have also shown promise. Initial response to outpatient treatment appears to be a particularly important in the selection of optimal continuing care interventions. In addition, stepped-care algorithms can reduce the cost and burden of treatment while maintaining good outcomes. Finally, matching treatment to specific problems present at intake or that emerge during treatment can also improve outcomes. Although all of these effects require replication and further refinement, the future of personalized care for alcohol dependence appears bright.

[1]  R. González-Sarmiento,et al.  Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis , 2012, Addiction biology.

[2]  K. Lynch,et al.  The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-month outcomes. , 2005, Archives of general psychiatry.

[3]  L. Ray,et al.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. , 2007, Archives of general psychiatry.

[4]  Jason M. White,et al.  OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence , 2011, Pharmacogenetics and genomics.

[5]  A. Cnaan,et al.  Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. , 2000, Alcoholism, clinical and experimental research.

[6]  S. Shiffman,et al.  Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. , 2007, Alcoholism, clinical and experimental research.

[7]  M. Srisurapanont,et al.  Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. , 2005, The international journal of neuropsychopharmacology.

[8]  S. Armeli,et al.  A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence: Moderation by Age of Onset and 5-Hydroxytryptamine Transporter-Linked Promoter Region Genotype , 2011, Journal of clinical psychopharmacology.

[9]  Raymond L. White,et al.  The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. , 2007, Journal of Clinical Psychopharmacology.

[10]  S. Murphy,et al.  Methodological Challenges in Constructing Effective Treatment Sequences for Chronic Psychiatric Disorders , 2007, Neuropsychopharmacology.

[11]  J. Gelernter,et al.  Genetics of alcohol dependence , 2009, Human Genetics.

[12]  C. Bouza,et al.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. , 2004, Addiction.

[13]  P. Muglia,et al.  α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking , 2008, Molecular Psychiatry.

[14]  Susan A. Murphy,et al.  A Conceptual Framework for Adaptive Preventive Interventions , 2004, Prevention Science.

[15]  G. A. Kenna.  Medications acting on the serotonergic system for the treatment of alcohol dependent patients. , 2010, Current pharmaceutical design.

[16]  Brigitte L. Kieffer,et al.  Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides , 1995, Cellular and Molecular Neurobiology.

[17]  D. Oslin,et al.  A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients , 2008, Psychopharmacology.

[18]  P. Friedmann,et al.  The effect of matching comprehensive services to patients' needs on drug use improvement in addiction treatment. , 2004, Addiction.

[19]  James R McKay,et al.  Do patient characteristics and initial progress in treatment moderate the effectiveness of telephone-based continuing care for substance use disorders? , 2005, Addiction.

[20]  H. Kranzler,et al.  Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. , 1996, Alcoholism, clinical and experimental research.

[21]  David Couper,et al.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. , 2006, JAMA.

[22]  C. Rück,et al.  A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. , 2007, The American journal of psychiatry.

[23]  John H. Krystal,et al.  Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking , 2007, Biological Psychiatry.

[24]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[25]  Antoinette Cullivan,et al.  Treating Substance Use Disorders with Adaptive Continuing Care , 2010 .

[26]  H. Smeets,et al.  A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. , 2007, Alcoholism, clinical and experimental research.

[27]  J. McGeary,et al.  Genetic moderators of naltrexone's effects on alcohol cue reactivity. , 2006, Alcoholism, clinical and experimental research.

[28]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[29]  R. Brooner,et al.  Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. , 2007, Drug and alcohol dependence.

[30]  L. Ray,et al.  A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. , 2004, Alcoholism, clinical and experimental research.

[31]  J. McKay,et al.  Continuing care for cocaine dependence: comprehensive 2-year outcomes. , 1999, Journal of consulting and clinical psychology.

[32]  Lei Yu.  The μ opioid receptor: from molecular cloning to functional studies , 1996, Addiction biology.

[33]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.

[34]  R. Brooner,et al.  Using Behavioral Reinforcement To Improve Methadone Treatment Participation , 2002, Science & practice perspectives.

[35]  R. Brooner,et al.  Combining Stepped-Care Approaches with Behavioral Reinforcement to Motivate Employment in Opioid-Dependent Outpatients , 2004, Substance use & misuse.

[36]  R. Brooner,et al.  A multicenter randomized evaluation of methadone medical maintenance. , 2002, Drug and alcohol dependence.

[37]  D. Oslin,et al.  Extended telephone-based continuing care for alcohol dependence: 24-month outcomes and subgroup analyses. , 2011, Addiction.

[38]  H. Edenberg,et al.  The contribution of genetics to addiction therapy approaches. , 2005, Pharmacology & therapeutics.

[39]  J. Hensler,et al.  Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. , 2000, JAMA.

[40]  E. Topol,et al.  The case for routine genotyping in dual-antiplatelet therapy. , 2010, Journal of the American College of Cardiology.

[41]  B. Rounsaville,et al.  Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. , 2003, Archives of internal medicine.

[42]  D. Oslin,et al.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[43]  Sylvain Houle,et al.  Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study , 2007, Biological Psychiatry.

[44]  J. Hoenicka,et al.  Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? , 2005, Alcohol and alcoholism.

[45]  S. Armeli,et al.  Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment , 2013, Addiction biology.

[46]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[47]  J. Monterosso,et al.  Predicting treatment response to naltrexone: the influence of craving and family history. , 2001, The American journal on addictions.

[48]  D. Oslin,et al.  A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.

[49]  R. Rosenheck,et al.  Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. , 2007, Alcoholism, clinical and experimental research.

[50]  Ming D. Li,et al.  Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. , 2011, The American journal of psychiatry.

[51]  David Goldman,et al.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. , 2006, American journal of human genetics.

[52]  B. Walker,et al.  κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats , 2011, Neuropharmacology.

[53]  James R McKay,et al.  Adaptive Interventions in Drug Court , 2008, Criminal justice review.

[54]  R. Rosenheck,et al.  Naltrexone in the treatment of alcohol dependence. , 2001, The New England journal of medicine.

[55]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[56]  K. Hornik,et al.  Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. , 2004, Drug and alcohol dependence.

[57]  J. Long,et al.  μ opioid receptor gene variants: lack of association with alcohol dependence , 1997, Molecular Psychiatry.

[58]  F. Collins,et al.  The path to personalized medicine. , 2010, The New England journal of medicine.

[59]  G. Bischof,et al.  Evaluation of a telephone-based stepped care intervention for alcohol-related disorders: a randomized controlled trial. , 2008, Drug and alcohol dependence.

[60]  S. Armeli,et al.  Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. , 2008, Alcoholism, clinical and experimental research.

[61]  M. Clark,et al.  Reminder letter, tailored stepped-care, and self-choice comparison for repeat mammography. , 2003, American journal of preventive medicine.

[62]  E. Löyttyniemi,et al.  Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. , 2007, Alcoholism, clinical and experimental research.

[63]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[64]  R. Feinn,et al.  Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. , 2006, Drug and alcohol dependence.

[65]  C. Lerman,et al.  Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes , 2009, Journal of neurogenetics.

[66]  K. Evers,et al.  Personalized medicine in psychiatry: ethical challenges and opportunities , 2009, Dialogues in clinical neuroscience.

[67]  C. Benkelfat,et al.  Serotonin and alcohol intake, abuse, and dependence: Clinical evidence , 1994, Biological Psychiatry.

[68]  E. Ochoa Mangado.  [Naltrexone in the treatment of alcohol dependence]. , 1998, Actas luso-espanolas de neurologia, psiquiatria y ciencias afines.

[69]  J. McKay.  Treating Substance Use Disorders with Adaptive Continuing Care , 2009 .